Physician profile
Ruby Jane Sia
NPI 1518061860
$8,391.94
in general payments reported to CMS, 2019-2025
44 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $1,354 · 2021: $1,756 · 2022: $1,314 · 2023: $982 · 2024: $961 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,213.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $965.75 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Corcept Therapeutics | $722.56 | 2019-2025 | Korlym |
| Abbott Laboratories | $668.42 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $606.29 | 2019-2025 | Mounjaro |
| Amgen INC. | $486.96 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Glaxosmithkline, LLC. | $442.15 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $388.35 | 2019-2025 | |
| Allergan, INC. | $329.05 | 2019-2021 | |
| Novo Nordisk INC | $264.50 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $261.67 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $188.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $184.55 | 2019-2023 | |
| Recordati_rare_diseases_inc. | $152.25 | 2021 | |
| Medtronic, INC. | $144.74 | 2025 | Interstim |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Jane Sia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.